Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis TELESTA THERAPEUTICS INC T.TST

Healthcare Biotechnology
"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

Opinion & Analysis (TSX:TST)

    Why I doubled my position in Telesta Therapeutics

    Sujan Lahiri September 21, 2015

    Rare earth collapse signals China’s upcoming economic crisis

    Stockhouse Editorial August 28, 2015

    Physical gold demand soared as price tumbled in 2013

    Stockhouse Editorial January 3, 2014

    Time to buy more Bioniche (T.BNC) shares?

    Stockhouse Editorial October 29, 2013

    Bioniche (T.BNC) settles with dissidents: report

    Stockhouse Editorial September 13, 2013

    Why Bioniche shareholders are angry

    Stockhouse Editorial June 13, 2013

    Bioniche digs in for fight with dissidents

    Peter Kennedy May 31, 2013

    Chemaphor in U.S. spotlight

    Stockhouse Editorial April 20, 2012